Dermatitis News

NEW ORLEANS — Pregnant women with eczema or psoriasis may need to exercise increased caution when evaluating treatment options, according to a presentation at the American Academy of Dermatology Annual Meeting.

SAN ANTONIO — Remibrutinib displayed sustained efficacy for chronic spontaneous urticaria with a favorable safety profile over 52 weeks, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Dupilumab was associated with improved clinical, safety and quality of life parameters in older patients with moderate to severe atopic dermatitis, according to findings from a post-hoc analysis of four studies.

NEW ORLEANS — Advancements in atopic dermatitis treatment have allowed prescribers and patients to choose between various options, according to a presenter at the American Academy of Dermatology Annual Meeting.

NEW ORLEANS — A greater proportion of patients with atopic dermatitis experienced complete IGA improvement with CBP-201 vs. vehicle, according to a study presented at the American Academy of Dermatology Annual Meeting.

The European Commission approved Dupixent in the European Union for the treatment of severe atopic dermatitis in infants and young children who are candidates for systemic therapy, Sanofi and Regeneron announced in a press release.

NEW ORLEANS — In this Healio video exclusive from the American Academy of Dermatology Annual Meeting, Neal Koller, founder and CEO of Alphyn Biologics, discusses the clinical-stage company’s drug pipeline.

NEW ORLEANS — In patients with atopic dermatitis, skin phenotypes were similar between East African and African American individuals in comparison with those of European American ethnicity, according to a presenter here.

NEW ORLEANS — Johnson & Johnson presented data in multiple areas at the American Academy of Dermatology Annual Meeting.

NEW ORLEANS — Patients with hand and foot atopic dermatitis experienced significant improvement with dupilumab, which sustained an acceptable safety profile, according to phase 3 study results presented here.